title: Investigation of the influenza-like symptoms associated with recombinant human erythropoietin therapy.
abstract: The mechanism by which fever and influenza-like symptoms occur, after the administration of recombinant human erythropoietin (rHuEPO) to patients on continuous ambulatory peritoneal dialysis, was investigated. Peripheral blood mononuclear cells, obtained from two patients with fever and/or influenza-like symptoms related to the administration of rHuEPO for the treatment of anaemia were cultured with or without rHuEPO (100, 200, and 300 U/ml). Production of interleukin-1 beta and tumour necrosis factor-alpha was higher in cultures with rHuEPO than in cultures without rHuEPO, although the dose relationships were not clear. These findings suggest that increased production of interleukin-1 beta and tumour necrosis factor-alpha 1, induced by administration of rHuEPO, may cause fever and influenza-like symptoms.
authors.affiliation: Second Department of Internal Medicine, Hiroshima University School of Medicine, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Takemasa
authors.forename: N
authors.initials: N
authors.lastname: Yorioka
authors.forename: M
authors.initials: M
authors.lastname: Yamakido
mesh_terms: D000328:Adult; D000740:Anemia / Q000188:drug therapy / Q000209:etiology; D002478:Cells, Cultured; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005334:Fever / Q000209:etiology*; D005921:Glomerulonephritis / Q000150:complications / Q000628:therapy; D006801:Humans; D007275:Injections, Intravenous; D007375:Interleukin-1 / Q000032:analysis* / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000187:drug effects* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis* / Q000187:drug effects / Q000276:immunology
chemical_list: D007375:Interleukin-1; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D004921:Erythropoietin